Pharmacodynamic Equivalence of Ramipril 10 mg and Atorvastatin 40 mg Administered as a Cardiovascular (CV) Polypill Acetylsalicylic Acid-Atorvastatin-Ramipril (AAR) as Compared to Monotherapy

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 528 participants.

Also called NCT02791958

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 528 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT02791958
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02791958. Randomized; no masking; primary purpose treatment. Start 2016-03 (registry gives no type); primary completion 2017-10 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Pharmacodynamic Equivalence of Ramipril 10 mg and Atorvastatin 40 mg Administered as a Cardiovascular (CV) Polypill Acetylsalicylic Acid-Atorvastatin-Ramipril (AAR) as Compared to Monotherapy
Condition
Hypertension
Intervention (Drug)
Cardiovascular Fixed Dose Combination Pill AAR
Intervention (Drug)
Atorvastatin 40 mg
Intervention (Drug)
Ramipril 10 mg
Lead sponsor
Ferrer Internacional S.A. (class: industry)

Record details

Record id
cardio:ct-nct02791958
Content hash
e11b783ae09cc8c110879eabd530851d4fc7783ff388d691c99a1c42d2e9f668